News and analysis on disease research and diagnostics.
The firm said it is drawing up plans for its business in a post-pandemic world, planning the introduction of new testing panels and enhancing its respiratory panel.
During a conference call, company executives also discussed results from the SMART NIPT trial and their outlook for Natera's three businesses.
The company doesn’t expect significant revenue from the test this year, but executives said that they are already seeing positive reception trends.
The genomics company reported revenues of $20.2 million for the quarter, driven by growth in its pharmaceutical services business and other non-VA customers.
The company reported $112.4 million in revenues compared to $83.2 million in Q4 2019, beating the average Wall Street estimate of $106.6 million.
